CN105456426A - Medicinal composition for treating systemic lupus erythematosus - Google Patents

Medicinal composition for treating systemic lupus erythematosus Download PDF

Info

Publication number
CN105456426A
CN105456426A CN201511001664.0A CN201511001664A CN105456426A CN 105456426 A CN105456426 A CN 105456426A CN 201511001664 A CN201511001664 A CN 201511001664A CN 105456426 A CN105456426 A CN 105456426A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
radix
lupus erythematosus
systemic lupus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201511001664.0A
Other languages
Chinese (zh)
Inventor
刘学键
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Huazhicao Medical Technology Co Ltd
Original Assignee
Qingdao Huazhicao Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Huazhicao Medical Technology Co Ltd filed Critical Qingdao Huazhicao Medical Technology Co Ltd
Priority to CN201511001664.0A priority Critical patent/CN105456426A/en
Publication of CN105456426A publication Critical patent/CN105456426A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/716—Clematis (leather flower)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicinal composition for treating systemic lupus erythematosus, belonging to the technical field of traditional Chinese medicine. The medicinal composition is prepared from the following raw herbal materials: herba portulacae, ginseng, indigo naturalis, coptis chinensis, radix puerariae, henry clematis root, poria cocos, honeysuckle stem, yerbadetajo herb, lotus plumule, fructus gardeniae and liquorice. The medicinal composition has a function of remarkably adjusting the activity of T cell subset and has the advantages of fast effect and short treatment course in treating systemic lupus erythematosus; and moreover, the medicinal composition realizes a therapeutical effect on vasculitis with a remarkable curative effect and is safe and reliable and has a broad prospect in clinical application.

Description

A kind of pharmaceutical composition of systemic lupus erythematosus
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition of systemic lupus erythematosus.
Background technology
Systemic lupus erythematosus (sle), a kind of diffusivity, systemic autoimmune diseases, mainly involve mucocutaneous, skeletal muscle, kidney and central nervous system, multiple organ and the systems such as lung, heart, blood can also be involved simultaneously, show various clinical symptoms, in serum, multiple autoantibody and crucial immunological abnormality can be detected.It is careful that treatment for systemic lupus erythematosus (sle) needs, and only has radical cure systemic lupus erythematosus (sle) just can avoid complication.Wherein common with the complication of cardiovascular system.The hematological of lupus erythematosus is the most common with vasculitis, with extremity, patient often occurs that large stretch of cicatrix petechia of unknown cause is for main clinical manifestation, if do not find timely and treat and develop as one pleases, the limb end of finger tip, toe point will be caused to occur the serious consequence such as depression and ulcer necrosis.Current Western medicine cannot effective systemic lupus erythematosus, although Western medicine can control generation and the development of disease to a certain extent, but adverse effect is obvious, after drug withdrawal, the state of an illness easily recurs, and there is more side effect, therefore, there is great demand in the Chinese medicine of people to effective systemic lupus erythematosus.
Chinese patent application 201310241251.4 discloses a kind of pharmaceutical composition being used for the treatment of systemic lupus erythematosus (sle), and this pharmaceutical composition is obtained by following raw material: Cornu Bubali, Radix Arnebiae (Radix Lithospermi), Ramulus Euonymi, Mirabilitum crystallina part, Cortex Moutan, Caulis Sargentodoxae, the Fructus Kochiae, Rhizoma Paridis, Radix Rumicis Japonici are followed and Fructus Litseae.This pharmaceutical composition can effectively improve lupus erythematosus patients clinical symptoms, but is not very remarkable for the vasculitic effect of complication of systemic lupus erythematosus.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of pharmaceutical composition of systemic lupus erythematosus, this pharmaceutical composition can the misery that causes to patient of mitigation system lupus erythematosus and complication vasculitis thereof, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is: the pharmaceutical composition of systemic lupus erythematosus, and this pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 10-25 part, Radix Ginseng 9-20 part, Indigo Naturalis 8-15 part, Rhizoma Coptidis 8-15 part, Radix Puerariae 6-12 part, Radix Clematidis Henryi 6-12 part, Poria 3-9 part, Caulis Lonicerae 3-9 part, Herba Ecliptae 3-9 part, Plumula Nelumbinis 2-6 part, Fructus Gardeniae 3-6 part and Radix Glycyrrhizae 1-10 part.
Preferably, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 10 parts, Radix Ginseng 9 parts, Indigo Naturalis 8 parts, Rhizoma Coptidis 8 parts, Radix Puerariae 6 parts, Radix Clematidis Henryi 6 parts, 3 parts, Poria, Caulis Lonicerae 3 parts, Herba Ecliptae 3 parts, Plumula Nelumbinis 2 parts, Fructus Gardeniae 3 parts and 1 part, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 20 parts, Radix Ginseng 15 parts, Indigo Naturalis 12 parts, Rhizoma Coptidis 12 parts, Radix Puerariae 9 parts, Radix Clematidis Henryi 9 parts, 6 parts, Poria, Caulis Lonicerae 6 parts, Herba Ecliptae 6 parts, Plumula Nelumbinis 4 parts, Fructus Gardeniae 4 parts and 5 parts, Radix Glycyrrhizae.
Preferably, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 25 parts, Radix Ginseng 20 parts, Indigo Naturalis 15 parts, Rhizoma Coptidis 15 parts, Radix Puerariae 12 parts, Radix Clematidis Henryi 12 parts, 9 parts, Poria, Caulis Lonicerae 9 parts, Herba Ecliptae 9 parts, Plumula Nelumbinis 6 parts, Fructus Gardeniae 6 parts and 10 parts, Radix Glycyrrhizae.
Correspondingly, present invention also offers the preparation method of the pharmaceutical composition of described systemic lupus erythematosus, the preparation method of described pharmaceutical composition comprises the steps:
(1): get Herba Portulacae, wash away impurity, crushed after being dried, cross 80-100 mesh sieve, adding medical material gross weight 6-10 times amount volume fraction is the ethanol of 60-85%, microwave extraction 15-25 minute, microwave power is 300-500W, and Extracting temperature is 45-60 DEG C, filters and retains Herba Portulacae filtering residue, the extractum that relative density is 1.10-1.25 is surveyed, obtained Herba portulacae extract at filtrate reduced in volume to 60 DEG C;
(2): get Radix Ginseng, Indigo Naturalis, Rhizoma Coptidis, Radix Puerariae, Radix Clematidis Henryi, Poria, Caulis Lonicerae, Herba Ecliptae, Plumula Nelumbinis, Fructus Gardeniae and Radix Glycyrrhizae, wash away impurity, after dry, mixing is ground into coarse powder, merge with above-mentioned Herba Portulacae filtering residue, add the purified water of medical material total amount 6-12 times amount, soak 20-30 minute, reflux, extract, 1-3 time, each 3-6 hour, filter, merging filtrate, the extractum that relative density is 1.10-1.25 is surveyed at filtrate reduced in volume to 60 DEG C, cooling, slowly add ethanol while stirring to alcohol content for reaching 45-60%, 4 DEG C of standing 12-24 hour, filter and retain filtering residue, obtain filtrate A,
(3): the filtering residue obtained in (2) slowly being added while stirring its weight 3-6 times amount volume fraction is the ethanol of 45-60%, 4 DEG C of standing 3-6 hour, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 1-2 time of 45-60% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, the extractum that relative density is 1.10-1.25 is surveyed under being evaporated to 60 DEG C of conditions after mixing;
(5): extractum obtained in described Herba portulacae extract and (4) is merged, stir, vacuum belt type drying is carried out at 60 DEG C of temperature, drying pressure is 0.02-0.08MPa, charging rate is 12L/h, and material strip transfer rate is 28cm/min, is pulverized by dry extract after drying, cross 100-200 mesh sieve, to obtain final product.
Preferably, described pharmaceutical composition is made into powder, tablet or capsule.
Source, the nature and flavor of the present invention's component used, return through and effect:
Herba Portulacae: this product is portulacaceous plant Herba Portulacae; Sour in the mouth, cold in nature; Clearing away heat-damp and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.
Radix Ginseng: this product is the dry root of Araliaceae Radix Ginseng; Sweet in the mouth, micro-hardship, property is put down; Return spleen, lung, heart channel; Strongly invigorating primordial QI, multiple arteries and veins takes off admittedly, and invigorating the spleen to benefit the lung, promotes the production of body fluid, and calms the nerves.
Indigo Naturalis: this product is acanthaceous vegetable acanthaceous indigo, the leaf of polygonaceae plant polygonum tinctorium ait. or cruciferae isatis or stem and leaf be through processing obtained dried powder or agglomerate; Cold in nature, salty in the mouth; Return Liver Channel; Heat-clearing and toxic substances removing, blood cooling and ecchymoses removing, pathogenic fire purging is calmed the frightened.
Rhizoma Coptidis: this product is the dry rhizome of ranunculaceae plant Rhizoma Coptidis; Bitter in the mouth, cold in nature; GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel; Heat clearing and damp drying, eliminating fire and detoxication.
Radix Puerariae: this product is the dry root of legume pueraria lobata or Radix Puerariae rattan; Cool in nature, gas is put down, sweet in the mouth; Heat clearing away, pathogenic fire reducing, toxin expelling.
Radix Clematidis Henryi: this product is root or the leaf of cohosh henry clematis; Acrid in the mouth, hardship, cool in nature; GUIXIN, lung, stomach warp; Heat-clearing and toxic substances removing, eliminating phlegm and relieving cough, promoting flow of QI and blood, pain relieving.
Poria: this product is the dry sclerotia of On Polyporaceae Poria; Sweet in the mouth, light, property is put down; GUIXIN, lung, spleen, kidney channel; Promoting diuresis to eliminate damp pathogen, spleen invigorating mind calming.
Caulis Lonicerae: this product is the dry stem branch of caprifoliaceae plant Radix Ophiopogonis; Sweet in the mouth, cold in nature; Attach to the lung and stomach meridians; Heat-clearing and toxic substances removing, dispelling wind dredging collateral.
Herba Ecliptae: this product is the dry aerial parts of feverfew Eclipta prostrata; Sweet in the mouth, cold in nature; Return kidney, Liver Channel; Nourishing the liver and kidney, cooling blood for hemostasis.
Plumula Nelumbinis: this product is the green radicle (Plumula Nelumbinis) in the middle of the mature seed of nymphaeaceae plant lotus; Bitter in the mouth, cold in nature; GUIXIN, kidney channel; Clear away heart-fire, reduce phlegm and internal heat, hemostasis, arresting seminal emission.
Fructus Gardeniae: this product is the dry mature fruit of Maguireothamnus speciosus Fructus Gardeniae; Property bitter, taste is trembled with fear; GUIXIN, lung, tri-jiao channel; Pathogenic fire purging relieving restlessness, clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Compared with prior art, the present invention has following technical advantage:
(1) compared with current chemotherapeutic agent, pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and pharmaceutical composition effect of the present invention is comprehensive, and medication effect is better, improves the quality of life of patient.
(2) in pharmaceutical composition of the present invention containing multi-medicament component, can effective systemic lupus erythematosus by synergism, and can significantly reduce systemic lupus erythematosus disease, the compliance of raising patient.
Therefore, the present invention also this pharmaceutical composition claimed preparing the application in medicament for treating systemic lupus erythematosus.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
Embodiment 1:
The embodiment of the present invention 1 pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 10 parts, Radix Ginseng 9 parts, Indigo Naturalis 8 parts, Rhizoma Coptidis 8 parts, Radix Puerariae 6 parts, Radix Clematidis Henryi 6 parts, 3 parts, Poria, Caulis Lonicerae 3 parts, Herba Ecliptae 3 parts, Plumula Nelumbinis 2 parts, Fructus Gardeniae 3 parts and 1 part, Radix Glycyrrhizae.
Preparation method is as follows:
(1): get Herba Portulacae, wash away impurity, crushed after being dried, cross 90 mesh sieves, adding medical material gross weight 8 times amount volume fraction is the ethanol of 75%, microwave extraction 20 minutes, microwave power is 400W, and Extracting temperature is 50 DEG C, filters and retains Herba Portulacae filtering residue, the extractum that relative density is 1.20 is surveyed, obtained Herba portulacae extract at filtrate reduced in volume to 60 DEG C;
(2): get Radix Ginseng, Indigo Naturalis, Rhizoma Coptidis, Radix Puerariae, Radix Clematidis Henryi, Poria, Caulis Lonicerae, Herba Ecliptae, Plumula Nelumbinis, Fructus Gardeniae and Radix Glycyrrhizae, wash away impurity, after dry, mixing is ground into coarse powder, merge with above-mentioned Herba Portulacae filtering residue, add the purified water of medical material total amount 9 times amount, soak 25 minutes, reflux, extract, 2 times, each 4 hours, filter, merging filtrate, surveys the extractum that relative density is 1.20 at filtrate reduced in volume to 60 DEG C, cooling, slowly add ethanol while stirring to alcohol content for reaching 50%, 4 DEG C leave standstill 24 hours, filter and retain filtering residue, obtaining filtrate A;
(3): the filtering residue obtained in (2) slowly being added while stirring its weight 4 times amount volume fraction is the ethanol of 50%, 4 DEG C leave standstill 4 hours, filter, obtain liquor B and filtering residue; Filtering residue uses the washing with alcohol 2 times of 50% again, collects and merges cleaning mixture;
(4): merge described filtrate A, liquor B and cleaning mixture, the extractum that relative density is 1.20 is surveyed under being evaporated to 60 DEG C of conditions after mixing;
(5): extractum obtained in described Herba portulacae extract and (4) is merged, stirs, at 60 DEG C of temperature, carry out vacuum belt type drying, drying pressure is 0.05MPa, and charging rate is 12L/h, and material strip transfer rate is 28cm/min, after drying, dry extract is pulverized, cross 100 mesh sieves, to obtain final product.
Embodiment 2:
The embodiment of the present invention 2 pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 20 parts, Radix Ginseng 15 parts, Indigo Naturalis 12 parts, Rhizoma Coptidis 12 parts, Radix Puerariae 9 parts, Radix Clematidis Henryi 9 parts, 6 parts, Poria, Caulis Lonicerae 6 parts, Herba Ecliptae 6 parts, Plumula Nelumbinis 4 parts, Fructus Gardeniae 4 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 3:
The embodiment of the present invention 3 pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 25 parts, Radix Ginseng 20 parts, Indigo Naturalis 15 parts, Rhizoma Coptidis 15 parts, Radix Puerariae 12 parts, Radix Clematidis Henryi 12 parts, 9 parts, Poria, Caulis Lonicerae 9 parts, Herba Ecliptae 9 parts, Plumula Nelumbinis 6 parts, Fructus Gardeniae 6 parts and 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Pharmaceutical composition of the present invention is on the impact of systemic lupus erythematosus (sle) MRL/lpr mice
1. experiment material
1.1 laboratory animal
7 week age Healthy female kunming mice 12,7 week age, systemic lupus erythematosus (sle) (SLE) MRL/lpr female mice 60, was provided by Guangdong Medical Lab Animal Center.
1.2 Experimental agents
(1) pharmaceutical composition for preparing of the embodiment of the present invention 1, embodiment 2;
(2) prednisone acetate tablets (LanZhou FoCi Pharmacy Co., Ltd, the accurate word H62020884 of traditional Chinese medicines).
2. experiment grouping
7 week age, Healthy female kunming mice 12 was blank group, systemic lupus erythematosus (sle) (SLE) MRL/lpr female mice in 96 7 week age is divided into 8 groups at random by body weight, often organize 12, to be respectively in SLE model group, the embodiment of the present invention 1 high dose group, the embodiment of the present invention 1 dosage group, the embodiment of the present invention 2 low dose group and positive controls in dosage group, the embodiment of the present invention 1 low dose group, the embodiment of the present invention 2 high dose group, the embodiment of the present invention 2.
After all mice adaptabilities raise one week, each group of rat gives corresponding tested material by following dosage gavage: the high, medium and low dosage of the pharmaceutical composition that the other gavage embodiment of the present invention 1 of high, medium and low dosage component, embodiment 2 prepare, is respectively 6.0g/kg, 3.0g/kg and 1.5g/kg; The prednisone acetate tablets (LanZhou FoCi Pharmacy Co., Ltd, the accurate word H62020884 of traditional Chinese medicines) of positive controls gavage 1.5g/kg, blank group and SLE model group are with isopyknic distilled water gavage.
All test group administration every day 1 time, successive administration 25 days, gets blood for subsequent use, wins spleen at the end of administration.
3. experimental technique and result
3.1 pharmaceutical compositions of the present invention are on the impact of SLE T lymphocyte subsets in spleen of mice immunized
The preparation of PBS liquid: take 8.5gNaCl, 0.2gKCl, 2.85gNa 2hPO 412H 2o and 0.27gKH 2pO 4, with after 1L distilled water standardize solution and get final product;
The preparation of erythrocyte cracked liquid: take tris20.594g and be dissolved in 500-700ml distilled water, then adjust pH7.65 to 1L with 1MHCl, be mixed with tris solution; Again by 0.83%NH 4cl and tris solution in 9:1 ratio mixing after and get final product;
The preparation of Single-cell suspensions: the spleen of each group of mice is put into the culture dish filling cold PBS liquid and cleans, 3mlPBS grinding is added in glass homogenizer, filter with 200 order stainless (steel) wires again, centrifugal for Splenic vessel liquid with rotating speed 1500rpm/min centrifugal 10 minutes, abandon supernatant, and add erythrocyte cracked liquid 2.5ml, mixing, leave standstill and after 5 minutes, add PBS liquid 2ml termination lytic response again, with 1500rpm/min centrifugal 10 minutes again, abandoning supernatant, adds PBS after washing three times, under fluorescence microscope, calculate cell number with PBS.Above operation all need on ice.
Use above Single-cell suspensions, after meter cell number, cell concentration is adjusted to 5 × 10 6cells/ml.Each group is got a wherein mouse boosting cell sample and is done subgroup analysis, and the mouse boosting cell sample of adjusted concentration is added flow cytometry dedicated pipe, and two pipes prepared by every mouse boosting cell sample, and often pipe adds sample 100 μ l.
5 μ l anti-mouse fluorescent-tagged mAbs CD3(FITC are added at the first pipe containing sample dedicated pipe) and 3 μ l anti-mouse fluorescent-tagged mAbs CD4(PE), the second pipe adds 5 μ lCD3(FITC) and 3 μ l anti-mouse fluorescent-tagged mAbs CD8(PE).Room temperature black out hatches 30min, and each pipe adds 500 μ l sheath fluids, vibration mixing.Carry out upper machine analysis.Experimental result is in table 1.
Table 1 the present invention is on the impact of SLE T lymphocyte subsets in spleen of mice immunized
As shown in Table 1, contrast with blank group, SLE mouse model group CD 3+cD 4+lymphocyte level significantly declines, SLE mouse model group CD 3+cD 8+lymphocyte level significantly rises.Contrast with SLE model group, pharmaceutical composition of the present invention and positive controls can make SLE mice CD 3+cD 4+t lymphocyte significantly rises, and makes CD 3+cD 8+t lymphocyte significantly declines, and wherein the high dose group effect of pharmaceutical composition is better.And CD 3+cD 4+lymphocyte is helper T lymphocyte (Th), CD 3+cD 8+lymphocyte mainly plays inhibition regulating action, therefore shows, pharmaceutical composition of the present invention can correct the imbalance state of SLE mouse T cell subgroup.
3.2 pharmaceutical compositions of the present invention are on the impact of serum IL-10, anti-ds-DNA antibody content
By test kit operating instruction operational approach, adopt IL-10, anti-ds-DNA antibody test kit (Shanghai Ke Feng biological reagent company limited), measure the content of each group of mice serum IL-10, anti-ds-DNA antibody, experimental result is in table 2.
Table 2 the present invention is on the impact of SLE mice serum IL-10, anti-ds-DNA antibody content
Note: compare with blank group, *p<0.05, *p<0.01; Compare with SLE model group, #p<0.05, ##p<0.01; Compare with positive controls, △p<0.05.
As shown in Table 2, compared with blank group, IL-10 and the anti-ds-DNA antibody level of SLE model mice obviously raise; Compared with SLE model group, SLE mice serum IL-10 and the anti-ds-DNA antibody level content of the high, medium and low dosage group of pharmaceutical composition of the present invention significantly reduce, wherein drug regimen object height, middle dosage group effect are very significantly and be better than positive controls, and embodiment 2 groups is particularly remarkable.This shows, medicine of the present invention is remarkable for SLE mice therapeutic effect.
3.3 pharmaceutical compositions of the present invention are on the impact of SLE mouse retention microalbumin content
The collection of specimen and detection: in the 20th day mice is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.After sodium azide process, centrifugal (2000r/min) 10min, measures the mice urine 2ml of storage, and each group adds bromophenol blue (0.231mmol/L) developer 1ml, and mixing (preventing bubble), measures absorbance A with ultraviolet spectrophotometer under 600nm.The content size of absorbance A reflection microdose urine protein, A value is less, and microdose urine protein content is lower.
Experimental data carries out statistical procedures in accordance with the following methods: adopt SPSS10.0 statistical software, calculate data with mean ± standard deviation ( ) represent, many groups data compares employing variance analysis, compares and adopt t inspection in group.With p<0.05 for there being statistical significance.Experimental result is in table 3.
Table 3 pharmaceutical composition of the present invention on the impact of SLE mouse retention microalbumin content ( )
Note: compare with blank group, *p<0.05, *p<0.01; Compare with SLE model group, #p<0.05, ##p<0.01; Compare with positive controls, △p<0.05.
As shown in Table 3, compared with SLE model group, the high, medium and low dosage group of pharmaceutical composition of the present invention all significantly can reduce albuminous content in SLE mice urine, and pharmaceutical composition high dose group effect particularly significantly and be better than positive drug.This shows further, and pharmaceutical composition of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.

Claims (5)

1. the pharmaceutical composition of a systemic lupus erythematosus, it is characterized in that, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 10-25 part, Radix Ginseng 9-20 part, Indigo Naturalis 8-15 part, Rhizoma Coptidis 8-15 part, Radix Puerariae 6-12 part, Radix Clematidis Henryi 6-12 part, Poria 3-9 part, Caulis Lonicerae 3-9 part, Herba Ecliptae 3-9 part, Plumula Nelumbinis 2-6 part, Fructus Gardeniae 3-6 part and Radix Glycyrrhizae 1-10 part.
2. the pharmaceutical composition of systemic lupus erythematosus as claimed in claim 1, it is characterized in that, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 10 parts, Radix Ginseng 9 parts, Indigo Naturalis 8 parts, Rhizoma Coptidis 8 parts, Radix Puerariae 6 parts, Radix Clematidis Henryi 6 parts, 3 parts, Poria, Caulis Lonicerae 3 parts, Herba Ecliptae 3 parts, Plumula Nelumbinis 2 parts, Fructus Gardeniae 3 parts and 1 part, Radix Glycyrrhizae.
3. the pharmaceutical composition of systemic lupus erythematosus as claimed in claim 1, it is characterized in that, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 20 parts, Radix Ginseng 15 parts, Indigo Naturalis 12 parts, Rhizoma Coptidis 12 parts, Radix Puerariae 9 parts, Radix Clematidis Henryi 9 parts, 6 parts, Poria, Caulis Lonicerae 6 parts, Herba Ecliptae 6 parts, Plumula Nelumbinis 4 parts, Fructus Gardeniae 4 parts and 5 parts, Radix Glycyrrhizae.
4. the pharmaceutical composition of systemic lupus erythematosus as claimed in claim 1, it is characterized in that, described pharmaceutical composition is made up of the raw material of following weight portion: Herba Portulacae 25 parts, Radix Ginseng 20 parts, Indigo Naturalis 15 parts, Rhizoma Coptidis 15 parts, Radix Puerariae 12 parts, Radix Clematidis Henryi 12 parts, 9 parts, Poria, Caulis Lonicerae 9 parts, Herba Ecliptae 9 parts, Plumula Nelumbinis 6 parts, Fructus Gardeniae 6 parts and 10 parts, Radix Glycyrrhizae.
5. the pharmaceutical composition of the systemic lupus erythematosus as described in any one of claim 1-4, is characterized in that: described pharmaceutical composition is made into powder, tablet or capsule.
CN201511001664.0A 2015-12-29 2015-12-29 Medicinal composition for treating systemic lupus erythematosus Withdrawn CN105456426A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511001664.0A CN105456426A (en) 2015-12-29 2015-12-29 Medicinal composition for treating systemic lupus erythematosus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511001664.0A CN105456426A (en) 2015-12-29 2015-12-29 Medicinal composition for treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CN105456426A true CN105456426A (en) 2016-04-06

Family

ID=55594883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511001664.0A Withdrawn CN105456426A (en) 2015-12-29 2015-12-29 Medicinal composition for treating systemic lupus erythematosus

Country Status (1)

Country Link
CN (1) CN105456426A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114902A (en) * 1995-04-03 1996-01-17 刘枝芳 Lupus powder medicine and its preparation method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114902A (en) * 1995-04-03 1996-01-17 刘枝芳 Lupus powder medicine and its preparation method

Similar Documents

Publication Publication Date Title
CN103830577B (en) A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease
CN108524814A (en) A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose
CN104288245B (en) Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method
CN105434894A (en) Method for preparing traditional Chinese medicine composition for treating systemic lupus erythematosus
CN1706463A (en) Medicine for treating women&#39;s habitual abortion and threatened abortion
CN103055285B (en) Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof
CN102973708B (en) Anti-aging traditional Chinese medicine composition and preparation method thereof
CN111803600A (en) Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and preparation method
CN110898182A (en) Traditional Chinese medicine for treating liver-yang-hyperactivity and spleen-deficiency type ulcerative colitis and preparation system thereof
CN103316074B (en) Medicine composite of halenia corni extract, astragalus extract and liquorice extract as well as preparation and application of medicine composite
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN108721431A (en) A kind of Chinese medicine composition of re-scheduling metal and its application
CN102000319B (en) Preparation method of stomach warming and soothing tablets
CN102641402A (en) Preparation and quality control method of traditional Chinese medicine compound preparation for treating nephritis
CN107595954A (en) A kind of Chinese medicine composition for reducing body fat and treating Central obesity and its application
CN103505548B (en) Traditional Chinese medicine used for treating ulcerative colitis, and preparation method and detection method thereof
CN105456426A (en) Medicinal composition for treating systemic lupus erythematosus
CN105434601A (en) Method for preparing pharmaceutical composition for treating systemic lupus erythematosus
CN102258626A (en) Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof
CN105497485A (en) Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof
CN110664905A (en) Traditional Chinese medicine preparation for expelling wind and clearing away cold and preparation method thereof
CN104547514A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof
CN117045744B (en) Traditional Chinese medicine composition for tonifying qi and strengthening spleen and/or resolving phlegm and resolving masses as well as preparation method and application thereof
CN108403793B (en) Medicine for treating primary dysmenorrhea and preparation method thereof
CN102233084A (en) Chinese medicinal composition for treating prostatitis and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160406